Ebola Vaccine Revival for Congo Outbreak

A promising Ebola vaccine, initially developed in 2011, is now being re-evaluated for its potential to combat the current Bundibugyo outbreak in the Congo. Researchers are urgently assessing its efficacy after years of the vaccine sitting unused. This renewed focus highlights the ongoing challenges in infectious disease preparedness and the potential for revisiting previously developed medical countermeasures in the face of emerging health crises. The speed of deployment and effectiveness of this older vaccine will be critical in controlling the current outbreak.